Loading data for ATRA — first visit, this takes a few seconds.

알림

Atara Biotherapeutics Inc... (ATRA)

NasdaqGS: ATRA · 실시간 가격 · USD

9.70

+0.32 (3.41%)

종가 기준: Aug 21, 2026, 8:00 PM

9.70

+0.00%

애프터마켓: 4:10 PM

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

3.41% (1D)

데이터 없음

매수호가	6.9
시가총액	97.37M
매출 (ttm)	6.19M
순이익 (ttm)	-16.69M
	0.10
	-1.54
	n/a
	8.74
P/B (ttm)	-2.48
P/S (ttm)	15.72
실적 발표일	Nov 12, 2026

매도호가	12.09
거래량	27,063
평균 거래량 (20일)	78,690
시가	9.46
전일 종가	9.38
일중 범위	9.15 - 9.84
52주 범위	3.92 - 19.14
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

ATRA 소개

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, ...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Oct 16, 2014

직원 수 10

상장 거래소 NasdaqGS

티커 ATRA

웹사이트 https://www.atarabio.com

전체 기업 정보

재무 실적

2025년 Atara Biotherapeutics의 매출은 120.77M로, 전년 128.94M 대비 -6.33% 감소했습니다. 순이익은 32.69M로, -138.28% 감소했습니다.

재무제표

어닝 서프라이즈

Atara Biotherapeutics가 Aug 12, 2026에 분기 실적을 발표했습니다:

매출 $516K 예상치 하회 $0, 및 -99.47% 전년 대비 감소.

EPS -0.32 예상치 하회 -0.07, 및 -109.14% 전년 대비 감소.

다음 실적 발표

Atara Biotherapeutics Inc.의 실적 발표 예정일은 Nov 12, 2026, 정규장 중입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

2개월 전 · Investor's Business Daily

Biotech Stocks Surge As UniQure 'Nail-Biting Journey' Comes To An End

Biotech stocks climbed Wednesday after the Food and Drug Administration signaled the end of a "nail-biting journey" for UniQure.

3개월 전 · Zacks

ATRA Stock Shoots Up 82% in a Month: Here's What You Should Know

Atara stock soars 82% as the FDA outlines a regulatory pathway for its lead product candidate, tab-cel, reviving hopes for potential U.S. approval, after two prior CRLs.

3개월 전 · InvestorsHub

FDA Resubmission Path for Tab-cel Keeps Atara’s (ATRA) Regulatory Timeline Alive

Atara Biotherapeutics said the FDA outlined a potential pathway for resubmitting the tabelecleucel application after a recent Complete Response Letter. Key Investor TakeawaysAtara Biotherapeutics (NAS...

4개월 전 · Insider Monkey

Atara Biotherapeutics, Inc. (ATRA) Registers Possible Resale of 400K Common Shares Tied to HCR Warrant Exercise

We recently compiled a list of the 10 Best Cheap Stocks Under $10 to Buy in April. Atara Biotherapeutics, Inc. is among the best cheap stocks to buy. TheFly reported on March 17 that ATRA filed a pros...

5개월 전 · Associated Press Finance

Atara Biotherapeutics: Q4 Earnings Snapshot

ATRA) on Monday reported a loss of $3.4 million in its fourth quarter. The Thousand Oaks, California-based company said it had a loss of 25 cents per share. The drug developer posted revenue of $1.6 m...

2 페이지 중 1

Atara Biotherapeutics Inc... (ATRA)